Abstract:PurposeBullying is associated with a heightened risk for poor outcomes, including psychosis. This study aimed to replicate previous findings on bullying prevalence in clinical high-risk (CHR) individuals, to assess the longitudinal course of clinical and functional variables between bullied and non-bullied CHR and the association of bullying with premorbid functioning, clinical outcome, transition to psychosis and risk of violence.MethodsThe sample consisted of 691 CHR participants and 96 healthy controls. Participants reported whether they had experienced bullying and how long it had lasted. Assessments included DSM-5 diagnoses, attenuated psychotic symptoms, negative symptoms, social and role functioning, depression, stress, premorbid functioning, and risk of violence. The bullied and non-bullied CHR groups were compared at baseline and further longitudinally on clinical and functioning variables and transition to psychosis.ResultsBullying was more prevalent among CHR individuals than healthy controls. Bullied CHR had a higher prevalence of PTSD and more severe depression and stress at baseline than non-bullied CHR. There was no impact of bullying on clinical and functional variables over time. Bullying was not related to final clinical status or transition to psychosis. However, bullied participants had poorer premorbid functioning and a greater risk of violence.ConclusionWhile bullying may not impact the likelihood of CHR individuals to transition to psychosis, it may be a risk factor for development of the at-risk state and may be related to a greater risk of violence. Future studies should consider bullying perpetration among CHR individuals.

Prominent Geneticist Loses £3.5m Grant over Charges of Bullying

WHO Refers $29m Oxford Research Project to GMC for Misconduct

Cochrane Director's Expulsion Results in Four Board Members Resigning.

Stark exclusion of ethnic minorities in genetic research must change, say experts

Not Enough Cash Goes to Brain Tumour Research, Doctors Say

Freedom of Information: Can Researchers Still Promise Control of Participants' Data?

Bullying in clinical high risk for psychosis participants from the NAPLS-3 cohort

Retracted: Keloid Core Factor CTRP3 Overexpression Significantly Controlled TGF-β1-Induced Propagation and Migration in Keloid Fibroblasts

The price of fear: Estimating the financial cost of bullying and harassment to the NHS in England

Retracted: circZC3HAV1 Regulates TBC1D9 to Affect the Biological Behavior of Colorectal Cancer Cells

Retraction Note: BNIP1 inhibits cell proliferation, migration and invasion, and promotes apoptosis by mTOR in cervical cancer cells

Retracted: Effect of Previous Cancer History on Survival of Patients with Different Subtypes of Breast Cancer

Retracted: Overexpression of 14-3-3 δ Predicts Poor Prognosis in Extrahepatic Cholangiocarcinoma Patients

Cochrane Board Confirms Dismissal of Director at Appeal

Hmrc Closes Loophole That Allowed Tax Relief on Funding Medical Research

Retracted: Identification of Hearing Loss-Associated Variants of PTPRQ, MYO15A, and SERPINB6 in Pakistani Families

'Doing good science is hard': retraction of high-profile reproducibility study prompts soul-searching

Retracted: Aberrant Methylation and Differential Expression of SLC2A1, TNS4, GAPDH, ATP8A2, and CASZ1 Are Associated with the Prognosis of Lung Adenocarcinoma

How harassment is depriving universities of talent: a national survey of STEM academics in the UK

[Retracted] Tissue‐specific transplantation antigen P35B functions as an oncogene and is regulated by microRNA‐125a‐5p in lung cancer

WITHDRAWN: Oncogenic KRAS extrinsically induces an immunosuppressive microenvironment in lung adenocarcinoma